Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.

Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research

ANN ARBOR, MI | Posted on October 30th, 2007

Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.

During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.

"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.

"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.

NanoBio's line of anti-infectives are designed to wage a two-pronged attack against bacteria, viruses, and fungi using safe detergents along with high-energy nanoemulsions to physically disrupt pathogen membranes and lyse microbes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation. The absence of a specific metabolic target significantly reduces the likelihood of triggering resistant infections, he added.

"The addition of Dr. Sutcliffe, an internationally recognized anti- infective expert, will enable NanoBio to accelerate the number of product candidates we take into the clinic for preventing and treating a wide range of infections," said Baker.

####

About NanoBio(R) Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBio® Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000
Fax:734.302.9150

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

Announcements

Nano 'sandwich' offers unique properties: Rice University researchers simulate two-dimensional hybrids for optoelectronics February 27th, 2017

Dream Chip Technologies Presents First 22nm FD-SOI Silicon of New Automotive Driver Assistance SoC: Advanced driver assistance system (ADAS) computer vision SoC developed for European THINGS2DO project with working first silicon fabricated on GLOBALFOUNDRIES’ 22nm FD-SOI Platfor February 27th, 2017

Sandia use confined nanoparticles to improve hydrogen storage materials performance: Big changes from a small package for hydrogen storage February 25th, 2017

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project